← Back to Master Dashboard
⚠️ REVIEW OVERDUE (10/17/2026)
NEM
Newmont Corporation
● ActiveLast Review: 9/17/2026
LIVE MARKET SNAPSHOT📈 Open Chart ↗
FAIR VALUE TARGET+3.7x R:R
$180.00
+66.7% Target Upside
Intrinsic value upon catalyst delivery
HARD INVALIDATION STOP
$85.00
-21.3% Downside Floor
Kill-switch thesis breach point
PORTFOLIO SIZING1.40% NAV
HARD STOP LOSS$85.00 (-33.3%)
TARGET 1 (DE-RISK)$126.00
TARGET 2 (BASE)$180.00
⚡CORE RE-RATE CATALYST
Fundamental catalyst validation, resource growth, or cash flow generation.
🚨KILL SWITCH & INVALIDATION CONDITIONS
Sustained thesis invalidation or structural asset impairment.
🎯 STRUCTURED VALIDATION CHECKPOINTS
0 / 0 CompletedNo milestones recorded yet for this thesis.
📝 DEEP RESEARCH MEMO & VALUATION MODEL
Aggregated Multi-Account Holdings: Total 80 shares worth €8,462.90 (1.4% NAV across Davy 148, Davy 270, Brokerage).
Accounts Breakdown: Davy 270 (50 sh / €5,276.93) | Brokerage (30 sh / €3,185.97).
📰 AUDIT STREAM & RESEARCH NOTES
No tracking notes or automated news logs recorded yet for this thesis.